Can-Fite up after topical psoriasis therapy shows promise in pre-clinical model

Can Fite Biopharma

05/04/2022 13:10

** U.S.-listed shares of Israeli biotech co  CANF.N  rise
4.9% to $1.28 premarket
    ** Says it is developing a topical version of its
experimental oral psoriasis therapy Piclidenoson, which has
shown promise in pre-clinical model  urn:newsml:reuters.com:*:nBw50pDLMa
    ** In a pre-clinical model, topical Piclidenoson
significantly inhibited disease, which was calculated based on
observation of erythema, thickness, scaling and score of skin
lesions
    ** Piclidenoson is co's lead drug candidate; CANF is also
developing therapies for liver diseases and erectile dysfunction
    ** Topical treatments account for 41.7% of psoriasis drug
market which was valued at $11.37 bln in 2021 - Persistence
Market Research
    ** CANF expects to report top-line data from a late-stage
study of oral Piclidenoson in Q2
    ** U.S.-listed stock down ~5.4% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))